Search
-
First Quarter of 2016 - A Good Market, a Good Quarter
For the first quarter of 2016, Ipsos' revenue stands at €386.9 million, up 1.9% compared with the same period in 2015.
-
Who Will Win the Race to Treat NASH?
Non-alcoholic Steatohepatitis, or NASH, is a liver disease characterized by rising prevalence, low diagnosis and a lack of therapies approved for treatment. All of these factors combine to make NASH a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. Accordingly, the race is now on among several pharma companies to develop the first effective pharmacotherapy to treat NASH.
-
Revealing Implicit Brand Drivers
Research has shown now that implicit perceptions can be very different from explicit perceptions and that both types can have an impact on behavior.
-
[EVENT] The Ad Guide – Financial Services
Despite the recent downturn, HK remains a major Financial Services hub.
-
[EVENT] The Ad Guide – Quick Service Restaurants
Breakfast Event: With Hong Kong’s recent economic downturn and decline in tourism, Quick Service Restaurants face even more of a challenge in winning new customers and retaining loyal ones.
-
[EVENT] Customer Centricity Events in Asia
The regional series of events promotes EFM with live demos and client case studies.
-
4 Reasons To Do “In-The-Moment” Research
One of the many strengths of mobile research is that it can happen in-the-moment, or close to the moment of people’s experience. One of the many strengths of mobile research is that it can happen in-the-moment, or close to the moment of people’s experience. However, it is not always exploited to the fullest of its potential because we often fall back into familiar research methods.
-
Smarter Closed Loop Feedback
This white paper explores how to optimise the design of Enterprise Feedback Management and Voice of the Customer programmes to maximise the ROI and reduce customer complaints and churn.
-
Don’t Kill the Analyst Just Yet
Interview on how Ipsos applies text analytics, including the pitfalls to avoid.
-
Why Is It Such a Challenge to Treat PAH?
Pulmonary Arterial Hypertension (PAH) is a life-threatening, degenerative disease that severely compromises the function of both the pulmonary (lung) and cardiovascular (heart) systems. Despite current treatment options in PAH offering improvements in symptom control and quality of life factors, there continue to be significant challenges that compromise the effective management of this progressive and debilitating condition.